Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From WuXi Biologics

China First Domestic COVID-19 Antibody Therapy Moves Towards Green Light

Brii’s antibody combo therapy nears approval in China, based on data from a late-stage study conducted outside the country.

China Coronavirus COVID-19

Competition and Price Cuts Slow Strong IO Momentum In China

While strong growth in China's immuno-oncology sector continued in the last quarter, the momentum appears to be slowing, affecting by multiple factors including intense competition in the sector and price cuts related to reimbursement listing, while regulatory authorities have already warned about what they see as the wasting of resources on "redundant" development activities. 

China Sales & Earnings

China’s Top Regulator Upholds Tough Stance Against 'Redundant' Clinical Trials

China's Center for Drug Evaluation has issued fresh warnings that it will tighten reviews of anti-tumor drugs on the grounds that “redundant” development activities waste clinical resources.

China Clinical Trials

Some Winners Emerge Despite China’s Reimbursement Price-Cutting Scheme

Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.

China Sales & Earnings
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register